Current Support
Rosenau Family Research Foundation, “Enriching CF newborn screening outcomes through a precision personalized medicine strategy” (2025-2028). Levy, PI
Cystic Fibrosis Foundation & Seattle Children’s Hospital, “REACH-OB-23: A research study to advance the CF therapeutics pipeline for people without modulators” (2024-ongoing). Levy, Site PI
Vertex Pharmaceuticals, Inc., “Ridgeline: A phase 3, open-label study evaluating the long-term safety and efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor triple combination therapy in Cystic Fibrosis subjects 1 year of age and older” (2023-ongoing). Levy, PI
Vertex Pharmaceuticals, Inc., “Timberline: A phase 3 study evaluating the pharmacokinetics, safety, and tolerability of VX 121/Tezacaftor/Deutivacaftor triple combination therapy in Cystic Fibrosis subjects 1 through 11 years of age” (2023-ongoing). Levy, PI
Wisconsin Department of Health Services, “Congenital disorders” (2023-ongoing). Levy, PI
Cystic Fibrosis Foundation Therapeutics & Seattle Children’s Hospital, “CHEC-OB-17: Characterizing CFTR modulated changes in sweat chloride & clinical outcomes” (2017-ongoing). Levy, Site PI
Completed Support
Cystic Fibrosis Foundation, “CF Center” (2023-2025). Levy, Co-Director
Cystic Fibrosis Foundation, “Therapeutic development center” (2023-2025). Levy, Co-Investigator
Vertex Pharmaceuticals, “NEMO: A non-interventional study evaluating the impact of TRIKAFTA initiation on children and caregivers of children with Cystic Fibrosis aged 2-5 years in a real-world Setting” (2023-2024). Levy, PI
Cystic Fibrosis Foundation, “Simplify IP-19” (2020-2022). Levy, Site PI
The Legacy of Angels Foundation, “Assessing the added value of whole genome sequencing in cystic fibrosis newborn screening,” (2016-2019). Levy, Site PI
NIH/Office of the Director (DP2 OD007031), “Integration of genomics with genetics-molecular phenotypes for CF lung disease” (2010-2015). Levy, PI
NIH/NHLBI (R21 HL102523), “IL-1 family gene polymorphisms and susceptibility to P. aeruginosa in CF patients” (2010-2012). Levy, PI
NIH/NHLBI (K23 HL074202), “Family based analysis of modifiers of CF lung disease” (2003-2008). Levy, PI